PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9835279-19 1998 We conclude that in rat AMs in vivo: (1) both db-cAMP and P2Y-receptor stimulation summate with, rather than inhibit, LPS-induced upregulation of the iNOS mRNA, protein, and RNI; (2) ETOH and DETC inhibit LPS-induced upregulation of iNOS mRNA only when stimulated through the NF-kappaB pathway; and (3) ETOH inhibits both autacoid and LPS-stimulated formation of iNOS protein by a mechanism independent of its ability to suppress iNOS transcription. Bucladesine 46-53 nitric oxide synthase 2 Rattus norvegicus 150-154 11072090-7 2000 iNOS induction and NO production were attenuated by dexamethasone and dibutyryl cAMP and even more strongly so when combined. Bucladesine 70-84 nitric oxide synthase 2 Rattus norvegicus 0-4 9835279-6 1998 LPS-induced stimulation of iNOS is inhibited in vitro by db-cAMP and purine-2-Y (P2Y) receptor-mediated agonists. Bucladesine 57-64 nitric oxide synthase 2 Rattus norvegicus 27-31 11469895-10 2001 Both dbcAMP and glucagon decreased iNOS promoter activity in rat hepatocytes transfected with the murine iNOS promoter and decreased DNA binding of the transcription factor NF-kappaB. Bucladesine 5-11 nitric oxide synthase 2 Rattus norvegicus 35-39 9262374-12 1997 Thus, two distinct pathways exist for induction of iNOS mRNA in rat AM in vivo: an NF-kappaB pathway for LPS and cytokines inhibitable by ethanol and diethyldithiocarbamate and an NF-kappaB-independent pathway, refractory to inhibition by ethanol and diethyldithiocarbamate for db-cAMP and 2-mes-ATP. Bucladesine 278-285 nitric oxide synthase 2 Rattus norvegicus 51-55 10375811-0 1998 Up-regulation of LPS-induced iNOS activity in dibutyryl cyclic AMP-differentiated rat astrocytes. Bucladesine 46-66 nitric oxide synthase 2 Rattus norvegicus 29-33 10375811-11 1998 Cycloheximide and dactinomycin also suppressed enhancement of NOS activity stimulated by LPS/dBcAMP, both in nitrite production and citrulline assay, indicating that the enhancement of NOS activity was due to the expression of inducible NOS (iNOS) gene and protein. Bucladesine 93-99 nitric oxide synthase 2 Rattus norvegicus 227-240 10375811-11 1998 Cycloheximide and dactinomycin also suppressed enhancement of NOS activity stimulated by LPS/dBcAMP, both in nitrite production and citrulline assay, indicating that the enhancement of NOS activity was due to the expression of inducible NOS (iNOS) gene and protein. Bucladesine 93-99 nitric oxide synthase 2 Rattus norvegicus 242-246 9347086-8 1997 LPS and DB-cAMP each increased iNOS mRNA and protein in AM and RNI in the BAL fluid and ex vivo incubates of AM. Bucladesine 8-15 nitric oxide synthase 2 Rattus norvegicus 31-35 9347086-9 1997 However, the peak of the increase of iNOS mRNA occurred at 2 hr for DB-cAMP and 4 to 6 hr for LPS. Bucladesine 68-75 nitric oxide synthase 2 Rattus norvegicus 37-41 9347086-12 1997 In contrast, pretreatment of rats with ETOH did not affect DB-cAMP-mediated increases of iNOS mRNA in AM at any time but suppressed the amount of iNOS protein and RNI produced in DB-cAMP-stimulated AM. Bucladesine 179-186 nitric oxide synthase 2 Rattus norvegicus 146-150 9347086-16 1997 Also, since ETOH inhibited DB-cAMP-mediated increases in iNOS protein without affecting iNOS mRNA ETOH also acts at a post-transcriptional or translational site to inhibit iNOS protein in rat AM in vivo. Bucladesine 27-34 nitric oxide synthase 2 Rattus norvegicus 57-61 9231726-6 1997 Furthermore, cyclic AMP-elevating agents (dibutyryl cyclic AMP and forskolin) inhibited TNF-alpha/IL-1beta-induced and LPS-induced iNOS expression and nitrite accumulation. Bucladesine 42-62 nitric oxide synthase 2 Rattus norvegicus 131-135 9262374-1 1997 Inducible nitric oxide synthase (iNOS) mRNA is up-regulated in vivo by dibutyryl-cAMP (db-cAMP), the purine-2y receptor agonist 2-methylthio-ATP and Escherichia coli endotoxin lipopolysaccharide (LPS). Bucladesine 71-85 nitric oxide synthase 2 Rattus norvegicus 33-37 9262374-1 1997 Inducible nitric oxide synthase (iNOS) mRNA is up-regulated in vivo by dibutyryl-cAMP (db-cAMP), the purine-2y receptor agonist 2-methylthio-ATP and Escherichia coli endotoxin lipopolysaccharide (LPS). Bucladesine 87-94 nitric oxide synthase 2 Rattus norvegicus 33-37 9262374-3 1997 Their effects on db-cAMP- and 2-methylthio-ATP-stimulated iNOS mRNA remain undefined. Bucladesine 17-24 nitric oxide synthase 2 Rattus norvegicus 58-62 8594915-6 1995 Semiquantitative reverse transcriptase-polymerase chain reaction revealed increased iNOS mRNA in myocytes treated with FSK+IL-1 beta or DBcAMP+IL-1 beta vs. those treated with IL-1 beta alone. Bucladesine 136-142 nitric oxide synthase 2 Rattus norvegicus 84-88 8594915-7 1995 The addition of FSK or DBcAMP to IL-1 beta increased iNOS mRNA half-life over IL-1 beta treatment alone (10.6, 11.7 vs. 2.4 h, respectively). Bucladesine 23-29 nitric oxide synthase 2 Rattus norvegicus 53-57 9034831-5 1997 First, iNOS expression was also inhibited by agents such as isoproterenol and forskolin, which cause an elevation of cAMP levels, and by dibutyryl cAMP (dbcAMP), a cAMP stable analogue. Bucladesine 153-159 nitric oxide synthase 2 Rattus norvegicus 7-11 19229699-0 2009 The effects of DBcAMP on the expression of eNOS, iNOS and TGF-beta in rat heart tissue. Bucladesine 15-21 nitric oxide synthase 2 Rattus norvegicus 49-53 15558323-4 2005 The addition of glucagon-like-peptide 1 (GLP-1) or dibutyryl-cAMP to islets incubated with 20 mmol/l glucose results in a marked suppression of iNOS expression and activity, a reduction in ncNOS activity and increased insulin release. Bucladesine 51-65 nitric oxide synthase 2 Rattus norvegicus 144-148